June 10, 2020 / 10:11 AM / a month ago

BRIEF-Axovant Gene Therapies Reports Q4 Loss Per Share Of $0.54

June 10 (Reuters) - Axovant Gene Therapies Ltd:

* AXOVANT ANNOUNCES YEAR-END FINANCIAL RESULTS AND EXPECTED KEY CLINICAL MILESTONES IN Q4 2020

* Q4 LOSS PER SHARE $0.54

* Q4 EARNINGS PER SHARE ESTIMATE $-0.58 — REFINITIV IBES DATA

* CASH POSITION OF $80.8 MILLION AS OF MARCH 31, 2020 AND EXPECTED RUNWAY INTO SECOND CALENDAR QUARTER OF 2021

* DATA FROM COHORT 2 OF SUNRISE-PD PHASE 2 STUDY OF AXO-LENTI-PD IN PARKINSON’S DISEASE EXPECTED IN Q4 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below